FDA FINAL CME POLICY ALLOWS GENERAL STATEMENT ON OFF-LABEL USES INSTEAD OF DISCLOSURE FOR EACH USE DISCUSSED; WRITTEN AGREEMENTS LESS EMPHASIZED

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".